BioCentury
ARTICLE | Company News

Threshold, NIH deal

December 30, 2016 9:09 PM UTC

Threshold and NIH’s NCI partnered to conduct preclinical testing assessing the biotech’s TH-3424 (AST-106) against T cell acute lymphoblastic leukemia (ALL) xenograft cell lines, which highly express aldo-keto reductase family 1 member C3 (AKR1C3). TH-3424 is a prodrug that selectively releases a DNA bis-alkylating agent upon exposure to AKR1C3. ...